Madrigal's 15min Chart Indicates Bearish Signals with MACD & KDJ Death Crosses
ByAinvest
Thursday, Aug 28, 2025 3:17 pm ET1min read
IVA--
Yasmeen Rahimi, the analyst at Piper Sandler, set a $26 per share target for IVA. Rahimi highlighted that the Phase 3 NATiV3 trial for lanifibranor is expected to provide a topline readout, which could potentially be a stock-moving event. Additionally, Rahimi pointed out a significant valuation gap between Inventiva and Madrigal Pharmaceuticals (MDGL), whose lead candidate, Rezdiffra, became the first FDA-approved MASH therapy in 2024. The valuation disconnect presents a compelling buying opportunity for IVA, as its oral asset is already de-risked for the probability of success [1].
Meanwhile, Madrigal's stock has recently triggered a MACD Death Cross and KDJ Death Cross on August 28, 2025, at 15:15. These technical indicators suggest that the stock price is poised to continue declining, as the momentum has shifted towards a downward trend with potential for further decreases.
References:
[1] https://seekingalpha.com/news/4489664-inventiva-stock-surges-piper-sandler-bullish-view
MDGL--
Madrigal's 15-minute chart has recently triggered a MACD Death Cross and KDJ Death Cross at 08/28/2025 15:15. This technical indicator suggests that the stock price is poised to continue declining, as the momentum has shifted towards a downward trend with a potential for further decreases.
Inventiva Inc. (NASDAQ: IVA) saw its stock climb by approximately 15% on Wednesday, following Piper Sandler's launch of its coverage with an Overweight recommendation. The analyst firm cited Inventiva's lead candidate, lanifibranor, which is targeted at metabolic dysfunction-associated steatohepatitis (MASH), a liver condition [1].Yasmeen Rahimi, the analyst at Piper Sandler, set a $26 per share target for IVA. Rahimi highlighted that the Phase 3 NATiV3 trial for lanifibranor is expected to provide a topline readout, which could potentially be a stock-moving event. Additionally, Rahimi pointed out a significant valuation gap between Inventiva and Madrigal Pharmaceuticals (MDGL), whose lead candidate, Rezdiffra, became the first FDA-approved MASH therapy in 2024. The valuation disconnect presents a compelling buying opportunity for IVA, as its oral asset is already de-risked for the probability of success [1].
Meanwhile, Madrigal's stock has recently triggered a MACD Death Cross and KDJ Death Cross on August 28, 2025, at 15:15. These technical indicators suggest that the stock price is poised to continue declining, as the momentum has shifted towards a downward trend with potential for further decreases.
References:
[1] https://seekingalpha.com/news/4489664-inventiva-stock-surges-piper-sandler-bullish-view
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet